FDA Approves Autoinjector for Self-Administered Zilucoplan in Generalized Myasthenia Gravis

The U.S. Food and Drug Administration (FDA) has approved a once-daily autoinjector for zilucoplan (ZILBRYSQ), providing adults with generalized myasthenia gravis (gMG) a second self-administered delivery option for the complement inhibitor. This approval enhances convenience for patients managing this rare autoimmune condition.